Matritech
This article was originally published in The Gray Sheet
Executive Summary
Submits premarket approval application to FDA on Nov. 9 for its NMP22 test kit for detecting and monitoring bladder cancer. The kit is based on the company's nuclear matrix protein technology. Matritech plans to sell the test for $20-$30 each; "four or five tests per year could be required on patients needing frequent monitoring," the company notes. Other NMP assays in Matritech's pipeline include tests for breast, cervical, colorectal and prostate cancers